
Biotech Business - February 11, 2025
Abera announces promising results
Abera Bioscience reports that its first in vivo study with a novel nasal influenza vaccine candidate has delivered promising results in the mouse model.

Biotech Business - February 5, 2025
Aqilion resumes development of its TAK1-program
The company has resumed development of the its TAK1 program as the company has regained the control and ownership of the program.

Biotech Business - February 4, 2025
Aplagon announces EUR 7 million financing
The funding round was led by new investors Fåhraeus Startup and Growth (FSG), a Nordic venture capital fund, and European Innovation Council (EIC) Fund.

Acquisition - January 31, 2025
WntResearch carries out a conditional reverse acquisition of OPSY
WntResearch has entered into an agreement for the acquisition of all shares in the Swedish privately owned company OPSY for a purchase price of approximately SEK 120 million, to be paid with newly issued shares in WntResearch.

Biotech Business - January 27, 2025
Oncopeptides’ Pepaxti formally approved for full reimbursement in Italy
The positive reimbursement decision for Pepaxti (melflufen) has been published in the Italian Official Journal.

Biotech Business - January 27, 2025
FDA approves IV maintenance dosing of Leqembi for treatment of early Alzheimer’s in the US
The U.S. Food and Drug Administration (FDA) has approved BioArctic’s partner Eisai’s Supplemental Biologics License Application (sBLA) for Leqembi as a once every four weeks intravenous (IV) maintenance dosing.